Tanzania and WHO act on high-mortality Rift Valley fever
This article was originally published in Clinica
The high mortality and size of a number of outbreaks of Rift Valley fever (RVF) in Tanzania have triggered a swift response on the part of the WHO, with measures to intensify diagnostic testing, including active case detection. The first human case of this mosquito-transmitted viral zoonosis in a long time was recorded in early February. Since then, more than 130 suspected cases and at least 18 deaths (at March 23) have been reported in five regions (Arusha, Dodoma, Mangara, Morogoro and Tanga). Of these cases, only a small number have been laboratory-confirmed, at the WHO-accredited Kenya Medical Research Institute (KEMRI).
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.